pL-CRISPR.SFFV.tRFP Citations (9)

Originally described in: Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. PubMed Journal

---

Articles Citing pL-CRISPR.SFFV.tRFP

Articles
Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-kappaB Binding Sites. Chung CH, Allen AG, Atkins AJ, Sullivan NT, Homan G, Costello R, Madrid R, Nonnemacher MR, Dampier W, Wigdahl B. Mol Ther Nucleic Acids. 2020 Sep 4;21:965-982. doi: 10.1016/j.omtn.2020.07.016. Epub 2020 Jul 15. PubMed
Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways. Cho JH, Kim K, Kim SA, Park S, Park BO, Kim JH, Kim SY, Kwon MJ, Han MH, Lee SB, Park BC, Park SG, Kim JH, Kim S. Cell Death Differ. 2021 Mar;28(3):900-914. doi: 10.1038/s41418-020-00649-z. Epub 2020 Oct 27. PubMed
Phosphorylation of REPS1 at Ser709 by RSK attenuates the recycling of transferrin receptor. Kim SH, Cho JH, Park BO, Park BC, Kim JH, Park SG, Kim S. BMB Rep. 2021 May;54(5):272-277. PubMed
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Johnson J, Fridley BL, List AF. Blood Adv. 2021 Apr 27;5(8):2216-2228. doi: 10.1182/bloodadvances.2020003475. PubMed
CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Li S, Holguin L, Burnett JC. Mol Ther Methods Clin Dev. 2022 Jan 22;24:321-331. doi: 10.1016/j.omtm.2022.01.012. eCollection 2022 Mar 10. PubMed
Distinct but interchangeable subpopulations of colorectal cancer cells with different growth fates and drug sensitivity. Coppo R, Kondo J, Iida K, Okada M, Onuma K, Tanaka Y, Kamada M, Ohue M, Kawada K, Obama K, Inoue M. iScience. 2023 Jan 13;26(2):105962. doi: 10.1016/j.isci.2023.105962. eCollection 2023 Feb 17. PubMed
Hypoxia stabilizes SETDB1 to maintain genome stability. Park S, Cho JH, Kim JH, Park M, Park S, Kim SY, Kim SK, Kim K, Park SG, Park BC, Moon JH, Lee G, Kim S, Kim JA, Kim JH. Nucleic Acids Res. 2023 Nov 10;51(20):11178-11196. doi: 10.1093/nar/gkad796. PubMed
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. EMBO Mol Med. 2024 Mar;16(3):445-474. doi: 10.1038/s44321-024-00024-2. Epub 2024 Feb 14. PubMed
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. Cancer Discov. 2024 Dec 2;14(12):2509-2531. doi: 10.1158/2159-8290.CD-24-0093. PubMed

If you have published an article using this material, please email us at to have your article added to this page.